SharesThree weeks ago I discussed very preliminary reports of blot clots observed in people receiving the AstraZeneca vaccine, resulting in 13 countries suspending use of the vaccine. Initially the concern was the observation of various types of blood clots in the week following receiving the AstraZeneca vaccine for COVID-19. An initial review found that the total number of reported blood clots was within the expected range for the background occurrence. One critical aspect of a possible link between the AstraZeneca vaccine (to be clear, there is no concern about blood clots in other COVID vaccines) and CVST is the question – what is the background rate of these clots? However, they also stress that the benefits of getting the vaccine (the risk of not getting it) is greater than this risk of rare blood clots.